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Abstract
Induction of cytochrome P450 3A4 (CYP3A4) expression is often implicated in clinically relevant drug-drug interactions
(DDI), as metabolism catalyzed by this enzyme is the dominant route of elimination for many drugs. Although several DDI
models have been proposed, none have comprehensively considered the effects of enzyme transcription/translation
dynamics on induction-based DDI. Rifampicin is a well-known CYP3A4 inducer, and is commonly used as a positive control
for evaluating the CYP3A4 induction potential of test compounds. Herein, we report the compilation of in vitro induction
data for CYP3A4 by rifampicin in human hepatocytes, and the transcription/translation model developed for this enzyme
using an extended least squares method that can account for inherent inter-individual variability. We also developed
physiologically based pharmacokinetic (PBPK) models for the CYP3A4 inducer and CYP3A4 substrates. Finally, we
demonstrated that rifampicin-induced DDI can be predicted with reasonable accuracy, and that a static model can be used
to simulate DDI once the blood concentration of the inducer reaches a steady state following repeated dosing. This
dynamic PBPK-based DDI model was implemented on a new multi-hierarchical physiology simulation platform named
PhysioDesigner.
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Introduction
Cytochrome P450 enzymes (CYPs) are implicated in many
clinically relevant drug-drug interactions (DDI), as the metabolism
reactions catalyzed by this enzyme family are the dominant route
of elimination for the majority of drugs. Inhibition of the CYPs can
lead to an unwanted elevation in the blood level of drugs
administered concomitantly, which can result in life-threatening
adverse drug reactions [1,2]. Induction of CYP expression is not
normally considered to be a safety concern, but can lead to
inadequate drug efficacy [3]. For example, co-administration of
rifampicin and cyclosporine results in excess metabolism of
cyclosporine leading to allograft rejection in transplanted patients
[4–6]. Thus, predictions of in vivo DDIs from in vitro metabolism
data are becoming increasingly important during the process of
preclinical drug development.
Various mathematical models have been proposed to predict
potential clinical drug-drug interactions from in vitro data [7–10].
However, induction studies are generally more difficult to conduct
compared with inhibition studies, as they need a cell-based sys-
tem that allows evaluation of gene transcription and protein
expression. The simplest model is one in which a static score of
degree of induction is calculated from the average plasma
concentration of an inducer using in vitro EC50 and Emax estimates
[11,12]. The potential for induction-based DDI for any particular
drug combination is then predicted based on the proportion of the
drugs’ total body clearance attributable to the enzymes induced.
Dynamic models consider fluctuations in the levels of enzyme
activity [13–15]. The clearance rate of substrate drugs can be
dynamically altered by the acceleration of enzyme synthesis in an
inducer concentration-dependent manner. A recent study indicat-
ed that a dynamic model, although not a marked improvement
over the static model, tended to give better predictions for the 50
clinical DDI cases studied [16].
To date, the dynamic models reported are all indirect
pharmacokinetic/pharmacodynamic (PK/PD) models [13–15]
which assume that an inducer accelerates the enzyme synthesis
in a concentration-dependent manner. Since enzyme synthesis is
assumed to obey zero-order kinetics, the action of the inducer on
enzyme synthesis starts immediately. Therefore, the gradual
increase in CYP activity over several days’ exposure to the
inducer is attributed simply to the slow degradation rate of these
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enzymes. However, several studies have indicated that it takes at
least a few days for the mRNA to reach a maximum level [17,18].
To evaluate the kinetics of enzyme induction, it is important to
consider the time courses of sequential mRNA and enzyme
synthesis.
The present study is aimed at developing a hybrid simulation
model for predicting the dynamics of induction-based DDI, in
which a whole-body physiologically based pharmacokinetic
(PBPK) model and an enzyme transcription/translation dynamics
model are implemented. Feasibility of this hybrid model was
investigated using rifampicin, a well-characterized and potent
inducer of CYP3A4. Rifampicin is frequently used as a positive
control or calibrator for evaluating the CYP3A4 induction
potential of test compounds. Therefore, a large amount of in vitro
rifampicin data is available in the literature. In general, cultures of
primary human hepatocytes are believed to be the best in vitro
model for simulating in vivo conditions. However, considerable
functional variability of donor hepatocytes has been observed
[19,20]. To obtain non-biased parameters regarding transcription
and translation of CYP3A4, we systematically collected in vitro data
and analyzed them using an extended least squares method
[21,22] that allows the estimation of kinetic parameters while
taking inter- and intra-individual variability into account. Using
the parameters estimated from in vitro human hepatocytes, we then
predicted clinical pharmacokinetics of CYP3A4 substrate drugs in
the presence of concomitantly administered rifampicin.
Materials and Methods
Data Collection
The fmCYP3A4 values, i.e., the apparent contribution of CYP3A4
to drug oral clearance, were obtained for 15 CYP3A4 substrate
drugs in a previous report [23,24]. These values were estimated
from the increase in AUCoral of the drugs tested resulting from the
action of CYP3A4 inhibitors, as observed in 53 separate clinical
DDI studies [23]. AUCoral is the area under the blood concentra-
tion-time profile following oral administration. Information on the
pharmacokinetics of CYP3A4 substrate drugs when co-adminis-
tered with rifampicin (see Table S1) was also obtained from the
literature [25–40]. The dosage regimen of oral rifampicin was also
considered in the present analysis. Clinical pharmacokinetic data
of rifampicin with different oral dosage regimens were obtained
from a report by Acocella et al. [41]. In addition, in vitro rifampicin
induction data of CYP3A4 mRNA expression and/or enzyme
activity in primary cultures of human hepatocytes were also
collected [17,42–46].
Modeling of the induction dynamics of CYP3A4
expression in human hepatocytes
Following the onset of treatment of hepatocytes with rifampicin,
expression of CYP3A4 mRNA was up-regulated after an initial
time delay, and reached maximum level on day 2 [17]. Taking
into account that rifampicin induces expression of CYP3A4 via
activation of the pregnane X receptor (PXR), a dynamic model















where RIF, PXRact, RNA, and CYP are the concentration of
rifampicin, normalized amount of activated PXR, CYP3A4
mRNA level, and CYP3A4 enzyme level, respectively, CYP0,
EC50, Ki, and kinact are the baseline level of CYP3A4 enzyme,
concentration of rifampicin at half-maximum PXR activation, the
constant for negative feedback inhibition, and the inactivation rate
constant for activated PXR, respectively. krna,syn and krna,pxr are rate
constants for baseline and PXR-mediated synthesis of CYP3A4
mRNA, and krna,deg is the rate constant for its sequestration, while
kcyp,syn and kcyp,deg are rate constants for the synthesis and
sequestration of CYP3A4 enzyme. In the model, a delay in the
early phase of CYP3A4 mRNA expression after addition of the
inducer was assumed to be attributable to the time required for
activation of PXR, while the accelerated decay of this mRNA was
thought to result from the subsequent negative feedback inhibition
by PXR according to CYP3A4 level. In general, induction of
mRNA and subsequent CYP3A4 enzyme levels is evaluated as the
fold increase over the value observed on day 0. If the levels of
mRNA and enzyme return to their original values (RNA0 and
CYP0, respectively) by the removal of a stimulus, the following



























Since the considerable inter-donor variability of drug metabo-
lism by human hepatocytes has been attributed to variations in the
baseline level of the CYP3A4 activity present [20], an extended
least square analysis was performed by considering the effect of
inter-donor variability on CYP0 (that is, p and q). This analysis was
carried out using the ADVAN9 routine in NONMEM 7.2 (Icon,
Inc., Dublin, Ireland).
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Conventional modeling of the induction dynamics of
CYP3A4 activity









where ksyn and kdeg are rate constants for baseline synthesis and
sequestration of CYP3A4 enzyme, respectively. Assuming that the
level of enzyme prior to administration of rifampicin (CYP0) was
under the steady state, the following relationship should be
satisfied:
ksyn~kdeg:CYP0 ð12Þ
Replacing the ksyn of Eq. 11 and normalizing it with CYP0









An extended least square analysis was performed by considering
the effect of inter-donor variability on Emax. This analysis was
carried out using the ADVAN9 routine in NONMEM 7.2.
Analysis of CYP3A4 activity induction by a simple static
model
Using only 72-h data, the Emax and EC50 values for induction of






An extended least square analysis was performed by considering
the effect of inter-donor variability on Emax, similarly to the case of
the indirect effect model mentioned before.
Modeling of the clinical pharmacokinetics of rifampicin
following repeated oral dosing
PBPK models are mechanistically rigorous models that incor-
porate anatomical and biochemical information into descriptions
of pharmacokinetics. To construct PBPK models, measurements
of drug concentrations in each organ and tissue are required.
However, only blood and urine data are generally available in
clinic. As an intermediate approach, a PBPK model which gives
an abstracted blood compartment and considers only recirculation
between blood and liver has been utilized [7]. It has been
demonstrated that the simplified PBPK model allows in vitro-in vivo
extrapolation of hepatic drug metabolism [7]. Rifampicin clear-
ance is known to be a nonlinear saturable process that accelerates
during repeated oral dosing [41]. The simplified PBPK model was
modified taking this specialized aspect of rifampicin pharmacoki-






























where Cb and Ch are concentrations of the drug in the blood and
liver, respectively, and Vmax is the inducible maximum hepatic
elimination rate. V1, CLr, Qh, Rb, and Kp,h are the volume of
systemic circulation, renal clearance, hepatic plasma flow rate,
blood/plasma distribution ratio, and liver/plasma distribution
ratio, respectively. Vh, fup, Km, ka, FaFg, and D are the volume of
liver, fraction unbound in plasma, Michaelis-Menten constant for
hepatic elimination, absorption rate constant, product of fraction
absorbed and intestinal availability, and amount of oral dose,
respectively. kin, kout, and F are the rate constant for synthesis of
hepatic elimination activity, rate constant for decay of hepatic
elimination activity, and coefficient for auto-induction, respective-
ly. CLr and fup were assumed to be 1.8 L/h and 0.2 [47],
respectively. Qh and Vh were assumed to be 96.6 L/h and 1.4 L,
respectively [7]. Assuming that FaFg and Rb were both at unity, V1,
Km, ka, Kp,h, kin, kout, and F were estimated by curve-fitting to blood
concentration-time profiles following repeated oral dosing of
rifampicin with different doses [41]. The parameter estimation
procedure was carried out with the ADVAN9 routine in
NONMEM 7.2.
Simulation of drug-drug interactions with rifampicin
In the case of drugs that are mostly metabolized by the liver,






fmCYP3A4:IRz 1{fmCYP3A4ð Þ ð18Þ
where AUC and AUCind are areas under the blood concentration
profile in the absence and presence of an inducer, respectively.
fmCYP3A4 and IR are the fraction of the drug metabolized by
CYP3A4 and the relative activity of CYP3A4 induced by the
inducer, respectively. This equation has been derived using the
following assumptions: the substrate drug is eliminated solely by
the liver, and the induction of CYP3A4 in the intestine is
negligible. The fmCYP3A4 values for each substrate drug were
obtained from the literature [23,24]. In the previous article [24],
53 induction-based DDI data sets in human were collected and
compiled without any normalization, demonstrating that the
degree of DDIs could be comprehensively explained by the IR
values of various inducers determined from in vivo data by taking
simvastatin as a standard CYP3A4 substrate. In the present study,
only data for rifampicin were taken from the compiled data. The
IR value for rifampicin was estimated using in vitro parameters with
the following process: Using Eqs. 15–17, the unbound concentra-
tion of rifampicin in the liver (fup:Ch

Kp,h) was computed. By
substituting it for the variable RIF in Eq. 6 or 13, a time-course for
the degree of induction of CYP3A4 (CYP ’) in vivo was estimated by
Eqs. 6–8 or Eq. 13. The IR was defined as the average of CYP ’
over the interval.
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To simulate the blood concentration-time profile of a CYP3A4
substrate drug in the presence of rifampicin, a PBPK model for the
substrate, similar to that for rifampicin (Eqs. 15–17), was
considered. Assuming that hepatic elimination is linear, the












ka:FaFg:D:d(ti): exp {ka: t{tið Þð Þ
ð19Þ
where CLint,h depicts intrinsic clearance for the substrate.
Pharmacokinetic parameters for CYP3A4 substrates were ob-
tained by curve-fitting to their blood concentration profiles as has
been reported previously [7]. For simulation of DDI with





0z 1{fmCYP3A4ð Þð Þ ð20Þ
where CLindint,h and CL
0
int,h are intrinsic clearances for the substrate
in the presence and absence of rifampicin, respectively. Thus, two
PBPK models for the inducer and substrate were bridged with the
CYP3A4 induction dynamics model to compute the DDI with
rifampicin.
PHML-SBML hybrid simulation
Physiological Hierarchy Markup Language (PHML) is a
markup language that can explicitly describe the multi-level
hierarchical structures of physiological functions in mathematical
models. One of the remarkable features of PHML is that it enables
the embedding of Systems Biology Markup Language (SBML)
[48] models as a module. To make a DDI model more readable
and reusable, two PBPK models for both inducer and substrate
were stored in the PHML format, and connected to each other via
a functional module representing subcellular enzyme induction, of
which the contents were implemented in SBML. The PHML and
SBML models were developed using open source modeling
platforms, PhysioDesigner (formerly insilicoIDE) and CellDesigner,
respectively [49,50]. PhysioDesigner and CellDesigner are freely
available at http://physiodesigner.org and http://celldesigner.org.
Fig. 1 represents snapshots of the DDI model implemented in
the simulation platform. As shown in Fig. 1A, a PBPK model is
Figure 1. Snapshots of DDI models implemented in multi-hierarchical physiology simulation platforms. Fig. 1A represents a PBPK
model for rifampicin implemented on PhysioDesigner, and Fig. 1B represents a transcription/translation dynamics model for CYP3A4 following
administration of the drug, as implemented on CellDesigner. Fig. 1C represents a PBPK-based DDI model, where the enzyme induction model was
hybridized. Yellow and white rectangles represent the capsule module and functional module, respectively. Modules can communicate by
connecting their ports with an edge.
doi:10.1371/journal.pone.0070330.g001
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primarily composed of two modules corresponding to the intestinal
lumen and body. Between these modules, it is enough to pass only
the value of an intestinal drug absorption rate. To ensure
maintainability and scalability of the model, these modules were
capsuled to hide unnecessary values, and opened with only a port
to pass the absorption rate value. By connecting the ports with an
edge, these capsule modules can communicate with each other.
Each module was further modeled in a hierarchical manner. Using
a template/instance framework of PHML, the absorption rate was
calculated in the intestinal lumen module by summing up the
values from each of the instances corresponding to multiple doses.
The body module includes the functional modules for the liver and
blood, in addition to a module for common static variables.
Differential equations and variables were implemented in the liver
and blood modules. Upon developing PBPK models for an
inducer and a CYP3A4 substrate drug, the models were bridged
with a capsuled functional module for induction of CYP3A4
(Fig. 1B). The CYP3A4 induction module receives the unbound
concentration of the inducer in the liver from the inducer PBPK
model and provides the IR value for the substrate PBPK model.
However, the module was simply a frame, and its object was
implemented in a SBML format. Fig. 1C represents a SBML
model for induction of CYP3A4 developed using CellDesigner.
Results
Modeling of CYP induction dynamics
The pooled data set obtained from 24 different sources
comprised 43 and 40 data points for CYP3A4 enzyme activity
and mRNA expression levels, respectively. Considering the effect
of inter-donor variability on the baseline level of CYP3A4 activity,
an extended least square analysis was performed based on Eqs. 6–
8 (see Methods). The parameters EC50, kinact, krna,deg, kcyp,deg, p and q
were estimated to be 1.18 mM, 0.0530 h–1, 0.0282 h–1, 0.313, and
4.34, respectively, in addition to the inter-donor variability of CYP0
(v2) of 0.318. Interestingly, the kcyp,deg estimated was comparable to
the one that was previously optimized for better in vitro/in vivo
extrapolation (0.03 h–1) [51,52]. Fig. 2 represents simulated
surface plots for mean CYP3A4 activity and mRNA expression
as a function of concentration and time. Expression of mRNA
reached a maximum level at ,40 h following the onset of
incubation with rifampicin, whereas the peak of CYP3A4 activity
induction was delayed in comparison.
The data set for induction of CYP3A4 activity was also analyzed
based on a conventionally used indirect effect model. However,
simultaneous estimation of all parameters by curve fitting failed,
probably because estimation of kdeg requires a clear observation of
the maximally induced state in the profile. Alternatively, using the
kdeg value from the literature [51,52], the EC50 and Emax values
were estimated by curve-fitting. When the kdeg value was a default
value of the Symcyp simulator (0.0072 h–1), the EC50 and Emax
values were estimated to be 0.283 mM and 37.1, respectively, in
addition to a vEmax
2 of 0.726. When the kdeg corrected for more
accurate in vitro-in vivo extrapolation (0.03 h–1) [51,52] was used,
the EC50 and Emax values were estimated to be 0.269 mM and 16.7,
respectively, in addition to a vEmax
2 of 0.702.
When the analysis based on a simple static model was
performed using only 72-h data, the EC50 and Emax values were
estimated to be 0.281 mM and 14.8, respectively. The vEmax
2
value was 0.874.
Modeling of the clinical pharmacokinetics of rifampicin
Blood concentration-time profiles following repeated oral
administration of rifampicin were simultaneously analyzed to
estimate its pharmacokinetic parameters based on a simplified
PBPK model. The estimated ka, V1, Km, Kp,h, kin, kout, and F values
were 0.963 h–1, 17.2 L, 0.370 mg/L, 10.6, 0.0193 mg/h,
5.75610–4 h–1, and 8.64 L/mg, respectively. Fig. 3 represents
simulation curves for the blood concentration of rifampicin
when using different oral doses, together with experimentally
obtained values. To confirm the nonlinearity of rifampicin
pharmacokinetics, AUC0–12h for 300 mg b.i.d. (twice a day)
and 600 mg q.d. (once a day) were calculated (Fig. 4). Even
though the total daily dose is the same, the AUC0–12h for 300 mg
b.i.d. rifampicin was much smaller than that for 600 mg q.d. This
result could be successfully explained by considering it to be a
saturable elimination process. Auto-inducible elimination of
rifampicin was described by a concentration-dependent increase
in Vmax.
In vitro-in vivo extrapolation
Using Eqs. 15–17, the concentration of unbound rifampicin in
the liver was computed. The profile was convoluted into Eq. 6 to
estimate CYP3A4 induction under clinical conditions, assuming
that the mechanism of CYP3A4 induction is equivalent between in
vitro and in vivo states. Fig. 5 shows a simulation of CYP3A4
induction following repeated oral dosing of rifampicin. The level of
CYP3A4 activity was transiently increased, peaking on day 4, and
then stabilizing on day 6 or later. Fluctuation of CYP3A4 activity
arising from repeated dosing of rifampicin was minimal, unlike
that of the blood concentration of the drug. Therefore, a static
model for enzyme induction would be sufficient to describe the
DDI occurring after rifampicin has been repeatedly administered
for more than 5 days.
Table 1 summarizes clinical DDI results between rifampicin
and drugs known to be metabolized by CYP3A4. The IR values
were estimated as an average of CYP3A4 activity induction for
the day studied, according to the dose, dosing interval, and
number of days treated with rifampicin. Using IR and fmCYP3A4
for each drug, reduction of AUC because of co-administration of
rifampicin was calculated and compared with clinical data (Fig. 6).
The predictive correlation coefficient (Q2) and standard deviation
of prediction errors (SDEP) were 0.684 and 0.0630, respectively.
Thus, the reduction of AUC for various drugs was predicted with
fairly good accuracy when using in vitro parameters for CYP3A4
induction.
For comparison, prediction using an indirect effect model was
conducted. When the default kdeg value of the Simcyp simulator
(0.0072 h–1) and its corrected value for an in vitro-in vivo correlation
(0.03 h–1) were used [51,52], the Q2 values were 0.499 and 0.570,
respectively. In addition, the Q2 values were estimated to be 0.604
when the prediction was made by a simple static model, where the
average concentration of rifampicin in blood was calculated by
dividing its AUC by the dosing interval (i.e., 24 h). The predictions
provided by both cases were not as accurate as the presently
proposed model.
Simulation of non-steady state DDI using the PHML
model
Taking alprazolam as an example, of which the DDI was
investigated under short-term treatment with rifampicin, the early
phase of DDI was simulated. PBPK parameters for alprazolam
(see Table S2) were obtained by curve-fitting to its blood
concentration profile as has been reported previously [7], and
PBPK models for alprazolam and rifampicin were implemented in
PHML using PhysioDesigner. Fig. 7A shows simulations of the
blood concentration of alprazolam in the presence and absence of
co-administration of rifampicin. Both drugs were assumed to be
Prediction of Rifampicin-Induced Clinical DDI
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administered orally every 24 h. In the absence of rifampicin, the
blood concentration of alprazolam was increased stepwise
following repeated oral doses and eventually reached a steady
state. In contrast, in the presence of rifampicin the blood
concentration of alprazolam decreased in a time-dependent
manner and then reached a steady state at the lower level.
Fig. 7B represents comparison between simulation results and
measured clinical data [35]. The concentration profile of
alprazolam with rifampicin treatment was predicted well (SDEP:
0.760), using pharmacokinetic parameters of both drugs and
induction dynamics parameters for rifampicin. Pharmacokinetics
of other drugs with relatively shorter-term rifampicin treatment
were also simulated (see Figure S1), if the time-course data were
available.
Discussion
Rifampicin is a strong inducer of drug metabolizing enzymes
such as CYP3A4. Rifampicin binds to the nuclear receptor
pregnane X receptor (PXR). Once activated, PXR forms a
heterodimer with the retinoic receptor (RXR), translocates into
the nucleus, and acts as a transcriptional factor. Transactivation of
PXR by rifampicin is regulated in a complex manner. Rifampicin-
activated PXR is negatively regulated by the small heterodimer
partner (SHP), which can be induced by farnesoid X receptor
(FXR) ligands [53]. SHP was shown to prevent the PXR/RXR
heterodimer from binding to DNA in a pull-down assay, while
over-expression of SHP inhibited transactivation of PXR by
rifampicin [53]. However, rifampicin-activated PXR is known to
suppress expression of the SHP gene, while simultaneously
Figure 2. Curve-fitting to experimental data of the induction of CYP3A4 by rifampicin in human hepatocytes. Fig. 2A represents the
relative fold induction of CYP3A4 mRNA, while Fig. 2B represents that of the protein level determined by enzyme activity measurements. The data for
each donor is presented in a different color. The baseline-normalized data and corresponding equations, i.e., Equations 6–8, were used for this
analysis, assuming that inter-individual variability for induction is because of differences in baseline CYP3A4 activity. The surface curves represent the
averages.
doi:10.1371/journal.pone.0070330.g002
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interacting with HNF4a, SRC-1 and PGC-1a to initiate
transcription of the CYP3A4 gene [54]. As shown in Fig. 2, the
levels of CYP3A4 mRNA post administration of rifampicin (using
data compiled from the literature), appear to be highest at around
48 h. In the present analysis, these observations were regarded as a
consequence of gene expression regulatory networks and were
described using a simplified negative feedback model.
It has been observed that upon repeated oral administration, the
clearance of rifampicin increases because of self-induced metab-
olism [41,47]. Since the enzyme responsible for the metabolism of
rifampicin has recently been identified [55], it is still unclear
whether its expression can be induced by a PXR-mediated
mechanism, similar to CYP3A4 and other drug metabolizing
enzymes [56–58]. Therefore, in order to construct a PBPK model
for the analysis of rifampicin pharmacokinetics, a simple auto-
induction process was considered. Based on the blood concentra-
tion profiles of rifampicin following repeated oral dosing, seven
parameters for rifampicin were estimated. Simultaneous multiple
curve-fitting allowed robust estimation of the pharmacokinetic
parameters. Even the Kp,h appeared to be reasonably estimated,
despite the lack of hepatic distribution data. The Kp,h obtained
from the nonlinear regression analysis was 10.6, which fell within
the range of Kp,h values calculated from in vivo human biopsy data
(4.8–30.3) [59]. This was also confirmed using the tissue
composition-based equations reported by Poulin and Theil [60].
The Kp,h for rifampicin was estimated at 6.01 using a computed
octanol/water partition coefficient for rifampicin (logKow: 4.24,
obtained from EPI Suite, available at http://www.epa.gov/
opptintr/exposure/pubs/episuite.htm).
In vitro parameters for rifampicin were estimated assuming that




















































































Figure 3. Nonlinear curve-fitting to the blood concentration of
rifampicin with repeated oral administration. Clinical data
measured on day 1, 4, 6, and 14 (Ref. 40) were simultaneously analyzed
based on a PBPK model considering an auto-inducible metabolic
process (Eqs. 15–17). Theoretical curves are represented for each data
set. Keys: 300 mg, b.i.d. (m, dotted line); 600 mg, q.d. (N, broken line);

















Figure 4. AUC measurements of the blood concentration-time
profile for oral rifampicin with different dosage regimens. The
AUC values were calculated from clinical data (Ref. 40) using a
trapezoidal method. Note that 600 mg q.d. and 300 mg b.i.d. are the
same in terms of total daily dose.
doi:10.1371/journal.pone.0070330.g004









































Figure 5. Simulation of the induction of CYP3A4 following
repeated oral dosing of rifampicin. Fig. 5A represents the relative
fold induction of CYP3A4 enzyme activity, while Fig. 5B represents the
blood concentration of rifampicin following oral dosing of 600 mg q.d..
Equations 6–8 and 15–17 were used for this simulation.
doi:10.1371/journal.pone.0070330.g005
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its degradation was negligible during the time period of the
experiment. Even when the metabolism of rifampicin was
incorporated into the in vitro CYP3A4 induction model using a
reported generation rate of the metabolite [58], differences in
parameter estimation were at most 16% (data not shown). A
notable point of the analysis was that the parameter optimization
procedure could be carried out directly without providing the
kcyp,deg value. Because it was a parameter sensitive to the difference
in the initial slope between the mRNA and activity profiles. In a
conventional model which analyzes the activity profile alone, the
maximally induced state needs to be presented in the profile to
estimate the parameter. More interestingly, the kcyp,deg value
estimated (0.0282 h–1) was rather close to 0.03 h–1, which was
corrected for better in vitro/in vivo extrapolation [51,52], than a
default kdeg value of the Simcyp simulator (0.0072 h
–1). It has been
reported that the turnover half-lives for CYP3A4 determined by
various methods ranged from 10 to 140 h [61], which corresponds
to 0.005–0.07 h–1. Although more information is needed to define
an appropriate kdeg, the reasonable estimate was obtained from the
in vitro data.
The reduction of AUC because of rifampicin-induced DDI was
satisfactorily predicted from in vitroCYP3A4 induction data (Fig. 5).
The predictive correlation coefficient of the present dynamic
model (Q2: 0.684) was slightly better than that of a conventionally
used indirect effect model with the kcyp,deg of 0.0072 h
–1 (Q2: 0.499)
or 0.03 h–1 (Q2: 0.570). Since these models can deal with the
dynamics of CYP3A4 induction, the IRs for each drug were
calculated according to the dosage regimen. As shown in Fig. 5,
however, the level of CYP3A4 activity becomes stable on day 6 or
later. Since most of the clinical DDI evaluations were carried out
on these days (i.e. after 5 or more days of treatment with
rifampicin), even a static model could also describe DDI (Q2:
0.604). The advantage of dynamic models is that it allows the
simulation of DDI even at the early stages of treatment. The
present dynamic DDI model, which considers the induction of
Table 1. Prediction of DDIs for various CYP3A4 substrate drugs with concomitantly administered rifampicin.




rifampicin (mg) days AUC ratio Ref. ID
induction ratio (IR) of
CYP3A4 activity AUC ratio
alprazolam 0.75 450 4 0.12 35 9.25 (6.51–19.0) 0.14
atorvastatin 0.68 600 5 0.20 25 9.64 (6.81–19.7) 0.15
buspirone 0.99 600 5 0.088 28 9.64 (6.81–19.7) 0.10
cyclosporine 0.80 600 11 0.27 36 8.16 (5.81–16.5) 0.15
gefitinib 0.39 600 16 0.17 31 7.68 (5.48–15.5) 0.28
imatinib 0.28 600 11 0.26 26 8.16 (5.81–16.5) 0.33
mefloquine 0.44 600 7 0.32 38 8.63 (6.14–17.5) 0.23
midazolam 0.92 600 5 0.041 40 9.64 (6.81–19.7) 0.11
midazolam 0.92 600 9 0.12 27 8.36 (5.94–16.9) 0.13
nifedipine 0.78 600 7 0.082 37 8.63 (6.14–17.5) 0.14
prednisolone 0.18 480 30 0.49 30 6.55 (4.71–13.1) 0.50
simvastatin 1.00 600 9 0.090 27 8.36 (5.94–16.9) 0.12
simvastatin 1.00 600 5 0.14 29 9.64 (6.81–19.7) 0.10
telithromycin 0.49 600 7 0.14 39 8.63 (6.14–17.5) 0.21
triazolam 0.93 600 5 0.051 34 9.64 (6.81–19.7) 0.11
zolpidem 0.40 600 5 0.28 33 9.64 (6.81–19.7) 0.22
zopiclone 0.44 600 5 0.18 32 9.64 (6.81–19.7) 0.21
a) Fraction of the drug metabolized by CYP3A4 (fmCYP3A4) and clinical DDI data were taken from the article of Ohno et al. [24].
b) Clinical data were obtained from the articles shown with the reference ID (Ref. ID).
c) Induction ratio (IR) of CYP3A4 activity was calculated from daily dose and days of administration of rifampicin by using Eqs. 6–8 and 15–17. The values for IR were



















Figure 6. Correlation between predicted and observed AUC
values for various drugs co-administered with rifampicin. This
figure was produced using the values listed in Table 1. Error bars for
predicted values represent the standard deviation from the inter-
individual variability in baseline CYP3A4 activity. Not that this variability
was estimated using extended least squares analysis of in vitro data.
doi:10.1371/journal.pone.0070330.g006
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CYP at not only the activity level but also at the mRNA level, was
shown to successfully simulate the clearance time-course of
alprazolam, a drug known to be metabolized by CYP3A4 (Fig. 7).
Rifampicin is known to induce other CYP enzymes moderately,
as has also been described in the FDA guidance [62]. When
rifampicin is concomitantly administered, clearance of bupropion
(a CYP2B6 substrate), repaglinide (a CYP2C8 substrate), and
warfarin (a CYP2C9 substrate) increases 2.1,3.4 times [63],
2.3 times [64], and 2.3,3.8 times [65,66], respectively. As
compared with them, clearance of typical CYP3A4 substrates
was much more induced (,10 times) (Table 1). A review article
[67] compiled information on DDI with rifampicin and indicated
that rifampicin induces CYP3A4 more efficiently than other
CYPs, glucuronosyltransferases (UGTs), and p-glycoprotein.
Taking them into account, induction of other enzymes than
CYP3A4 would minimally affect the results of prediction, unless
the fmCYP3A4 of substrates was extremely low. Gefitinib (fmCYP3A4:
0.39) is known to be metabolized largely by CYP2D6 [68], which
is little induced by rifampicin. On the other hand, imatinib
(fmCYP3A4: 0.28) is metabolized by CYP2C8 to the similar extent
with CYP3A4 [69], resulting in slightly possible underestimation of
DDI due to rifampicin. Prednisolone (fmCYP3A4: 0.18) has been
reported not to be metabolized by any other CYPs than CYP3A4
or UGTs [70]. Although the reasons why the fmCYP3A4 of
prednisolone is low remain unclear, the fmCYP3A4 of 0.18 gave a
good prediction of the DDI due to rifampicin. As long as the
results were viewed as fair, induction of other enzymes or
transporters might not be important in determining DDI between
CYP3A substrates and rifampicin.
PHML, which inherited insilicoML (ISML) [71], is a new XML-
based specification to describe a wide variety of models of
biological and physiological functions with hierarchical structures.
It can describe mathematical models consisting of ordinary
differential equations, partial differential equations, agent-based
simulation models, and others. In a similar way to ISML [71], a
model is described by a set of functional elements (modules), each
of which specifies mathematical expressions of the module
functions. PhysioDesigner acts as a graphical editor and browser
of the models written in PHML or ISML. A notable feature of
PhysioDesigner is that it provides a function for creating SBML-
PHML hybrid models. Since SBML is widely distributed as a
standard format for representing and sharing models of biochem-
ical reaction networks, it enables us to create multi-level
physiological model systems. The functions of PhysioDesigner
allowed us to dynamically connect PBPK-based DDI models with
an enzyme transcription/translation dynamics model. Since the
module-based hybrid model is highly reusable, extension to more
comprehensive network models would be expected in future.
Supporting Information
Figure S1 Simulation of blood concentration of CYP3A4
substrate drugs following their oral administration.
Keys: sole administration ( N , solid line); 5-day pretreatment with
daily doses with 600 mg rifampicin (m, dash line). Pharmacoki-
netic parameters for each drug were estimated by curve-fitting to
the blood concentrations following the sole administration, and
then used for predicting those following co-administration with
rifampicin. The pharmacokinetic parameters are given in
Table S2.
(DOC)
Table S1 Pharmacokinetic data for CYP3A4 substrates.
(DOC)
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Figure 7. Simulation of DDI between alprazolam and rifampicin
using a PHML/SBML hybrid model. Fig. 7A represents blood
concentration profiles of repeated oral doses of alprazolam in the
absence (solid line) and presence (broken line) of rifampicin. Fig. 7B
represents the comparison between the predicted blood concentration
of alprazolam with the corresponding clinical data (Ref. 35). Keys: 1 mg
alprazolam alone (N, solid line); 1 mg alprazolam with 4-day pretreat-
ment with daily doses of 450 mg rifampicin (m, broken line). The
pharmacokinetic parameters for alprazolam were estimated by curve-
fitting to the blood concentrations following the sole administration
(standard deviation of residuals, RSD: 0.483), and then used for predicting
those following the concomitant administration (standard deviation of
prediction errors, SDEP: 0.760). Both RSD and SDEPwas the same in terms
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